Royalty Pharma PLC $RPRX is Regal Partners Ltd’s 10th Largest Position

Regal Partners Ltd raised its holdings in shares of Royalty Pharma PLC (NASDAQ:RPRX) by 6.7% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,435,126 shares of the biopharmaceutical company’s stock after acquiring an additional 89,930 shares during the quarter. Royalty Pharma makes up 3.6% of Regal Partners Ltd’s investment portfolio, making the stock its 10th biggest holding. Regal Partners Ltd owned about 0.25% of Royalty Pharma worth $50,631,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Watchtower Advisors LP purchased a new position in Royalty Pharma in the second quarter valued at approximately $3,603,000. Financiere des Professionnels Fonds d investissement inc. acquired a new stake in Royalty Pharma during the third quarter worth approximately $933,000. Nordea Investment Management AB lifted its position in shares of Royalty Pharma by 18.3% during the 3rd quarter. Nordea Investment Management AB now owns 775,999 shares of the biopharmaceutical company’s stock worth $27,137,000 after buying an additional 120,004 shares during the last quarter. World Investment Advisors acquired a new position in shares of Royalty Pharma in the 3rd quarter valued at $1,702,000. Finally, Generali Asset Management SPA SGR boosted its holdings in shares of Royalty Pharma by 7,752.8% in the 3rd quarter. Generali Asset Management SPA SGR now owns 34,081 shares of the biopharmaceutical company’s stock valued at $1,202,000 after buying an additional 33,647 shares in the last quarter. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Royalty Pharma Stock Down 0.6%

Shares of NASDAQ:RPRX opened at $45.41 on Friday. Royalty Pharma PLC has a 1-year low of $29.66 and a 1-year high of $47.86. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.40 and a quick ratio of 2.40. The stock has a market cap of $26.20 billion, a P/E ratio of 33.64 and a beta of 0.40. The firm has a fifty day moving average price of $42.54 and a 200 day moving average price of $39.22.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings data on Wednesday, February 11th. The biopharmaceutical company reported $1.46 EPS for the quarter, beating analysts’ consensus estimates of $1.33 by $0.13. Royalty Pharma had a net margin of 32.38% and a return on equity of 28.21%. The company had revenue of $621.99 million for the quarter, compared to analyst estimates of $839.97 million. Sell-side analysts predict that Royalty Pharma PLC will post 4.49 EPS for the current year.

Royalty Pharma Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 20th will be given a $0.235 dividend. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.22. The ex-dividend date is Friday, February 20th. This represents a $0.94 annualized dividend and a yield of 2.1%. Royalty Pharma’s payout ratio is presently 69.63%.

Analysts Set New Price Targets

Several brokerages recently commented on RPRX. Wall Street Zen lowered shares of Royalty Pharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 14th. TD Cowen restated a “buy” rating on shares of Royalty Pharma in a research note on Friday, February 27th. Citigroup raised their price objective on Royalty Pharma from $48.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, January 27th. UBS Group upgraded Royalty Pharma from a “neutral” rating to a “buy” rating and set a $49.00 target price on the stock in a research report on Friday, January 30th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $61.00 target price on shares of Royalty Pharma in a report on Thursday, February 12th. Six analysts have rated the stock with a Buy rating, According to data from MarketBeat, Royalty Pharma currently has an average rating of “Buy” and an average price target of $48.67.

Insider Activity at Royalty Pharma

In other Royalty Pharma news, CFO Terrance P. Coyne sold 34,791 shares of Royalty Pharma stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $46.78, for a total value of $1,627,522.98. Following the transaction, the chief financial officer directly owned 45,761 shares in the company, valued at approximately $2,140,699.58. This trade represents a 43.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Marshall Urist sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, January 30th. The shares were sold at an average price of $41.09, for a total value of $821,800.00. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 737,078 shares of company stock valued at $29,862,002. 18.90% of the stock is owned by company insiders.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.